Edward C. Stack

Dana-Farber Cancer Institute — United States

Medicine · Health Sciences

36h-index6.4kcitations133works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Bladder and Urothelial Cancer Treatments(26), Prostate Cancer Treatment and Research(23), Cancer Immunotherapy and Biomarkers(19), Immunotherapy and Immune Responses(16), Cancer Genomics and Diagnostics(13)

Publications131 total

SPINK1 immunohistochemistry: An ancillary tool to diagnose urothelial carcinoma in situ and urothelial dysplasia
Pathology - Research and Practice·2025
Data from Activating mTOR Mutations in a Patient with an Extraordinary Response on a Phase I Trial of Everolimus and Pazopanib
2023Open Access
Data from Opposing Effects of Androgen Deprivation and Targeted Therapy on Prostate Cancer Prevention
2023Open Access
Data Supplement from Activating mTOR Mutations in a Patient with an Extraordinary Response on a Phase I Trial of Everolimus and Pazopanib
2023Open Access
Supplementary Table 1 from Opposing Effects of Androgen Deprivation and Targeted Therapy on Prostate Cancer Prevention
2023Open Access
Supplementary Table S3 from Quantitative Analysis of Immune Infiltrates in Primary Melanoma
2023Open Access
Supplementary Table S2 from Quantitative Analysis of Immune Infiltrates in Primary Melanoma
2023Open Access
Supplementary Table 1 from Opposing Effects of Androgen Deprivation and Targeted Therapy on Prostate Cancer Prevention
2023Open Access
Supplementary Table S1 from Quantitative Analysis of Immune Infiltrates in Primary Melanoma
2023Open Access
Data Supplement from Activating mTOR Mutations in a Patient with an Extraordinary Response on a Phase I Trial of Everolimus and Pazopanib
2023Open Access
Supplementary Figures from Opposing Effects of Androgen Deprivation and Targeted Therapy on Prostate Cancer Prevention
2023Open Access
Supplementary Figure 1 from Activating mTOR Mutations in a Patient with an Extraordinary Response on a Phase I Trial of Everolimus and Pazopanib
2023Open Access
Supplementary Table S2 from Quantitative Analysis of Immune Infiltrates in Primary Melanoma
2023Open Access
Data from Quantitative Analysis of Immune Infiltrates in Primary Melanoma
2023Open Access
Supplementary Table S3 from Quantitative Analysis of Immune Infiltrates in Primary Melanoma
2023Open Access
SupplementaryTable S4 from Quantitative Analysis of Immune Infiltrates in Primary Melanoma
2023Open Access
Data from Activating mTOR Mutations in a Patient with an Extraordinary Response on a Phase I Trial of Everolimus and Pazopanib
2023Open Access
Supplementary Table 4 from Activating mTOR Mutations in a Patient with an Extraordinary Response on a Phase I Trial of Everolimus and Pazopanib
2023Open Access
Supplementary Figures from Opposing Effects of Androgen Deprivation and Targeted Therapy on Prostate Cancer Prevention
2023Open Access
Supplementary Table 4 from Activating mTOR Mutations in a Patient with an Extraordinary Response on a Phase I Trial of Everolimus and Pazopanib
2023Open Access
page 1 of 7Next →

Frequent Co-authors

Massimo Loda(20), Philip W. Kantoff(14), Rosina T. Lis(13), Robert J. Ferrante(10), Lorelei A. Mucci(8), Meir J. Stampfer(7), Karen Smith(7), Kerry Cormier(7), Neil E. Martin(6), Edward L. Giovannucci(6), Toni K. Choueiri(6), Joaquim Bellmunt(6), Hoon Ryu(6), Lillian Werner(6), Andreas Pettersson(5), Michelangelo Fiorentino(5), Sabina Signoretti(5), Jonathan E. Rosenberg(5), Steven J. Del Signore(5), Kathryn L. Penney(4)